CTIM-76
Phase 1Recruiting 0 watching 0 views this week💤 Quiet
25
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Platinum-resistant Ovarian Cancer
Conditions
Platinum-resistant Ovarian Cancer, Testicular Cancer, Endometrial Cancer
Trial Timeline
Jul 10, 2024 → Apr 30, 2028
NCT ID
NCT06515613About CTIM-76
CTIM-76 is a phase 1 stage product being developed by Context Therapeutics for Platinum-resistant Ovarian Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06515613. Target conditions include Platinum-resistant Ovarian Cancer, Testicular Cancer, Endometrial Cancer.
Hype Score Breakdown
Clinical
10
Activity
5
Company
2
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06515613 | Phase 1 | Recruiting |
Competing Products
16 competing products in Platinum-resistant Ovarian Cancer